Literature DB >> 26333213

Development of consensus International Classification of Functioning, Disability and Health (ICF) core sets for lymphedema.

P B Viehoff, Y F Heerkens, C D Van Ravensberg, J Hidding, R J Damstra, H Ten Napel, H A M Neumann.   

Abstract

To understand the challenges of patients with lymphedema it is important to describe functioning and to measure the effectiveness of treatment in changing functioning. The International Classification of Functioning, Disability and Health (ICF) offers an international framework to classify functioning of persons in their personal environment. ICF Core Sets are lists of selected ICF categories concerning those important aspects of functioning that are most likely to be affected by a specific health problem or disease. These Core Sets make it easier and faster to describe and communicate the patient's problems and to define treatment goals. Furthermore, they are available to health care providers of all professions, researchers, health insurance companies and policy-makers. The objective of this document is to present the outcomes of a consensus conference held to determine the first versions of the ICF Core Sets for lymphedema. Frequency rankings were made of the ICF categories derived from four preparatory studies, being: a) a systematic review; b) a qualitative study; c) an expert survey; and d) a cross-sectional study. By means of working group discussions and plenary sessions, a final consensus on ICF categories was achieved and Comprehensive and Brief Core Sets for lymphedema for the upper limb, lower limb, and midline lymphedema were defined. These ICF Core Sets contain different items in each region. Future validation of these Core Sets for health professions and for countries is needed.

Entities:  

Mesh:

Year:  2015        PMID: 26333213

Source DB:  PubMed          Journal:  Lymphology        ISSN: 0024-7766            Impact factor:   1.286


  4 in total

1.  Systematic analysis of parameters predicting pathological axillary status (ypN0 vs. ypN+) in patients with breast cancer converting from cN+ to ycN0 through primary systemic therapy (PST).

Authors:  C Liedtke; Hans-Christian Kolberg; L Kerschke; D Görlich; I Bauerfeind; T Fehm; B Fleige; G Helms; A Lebeau; A Stäbler; S Schmatloch; M Hausschild; L Schwentner; Gunter von Minckwitz; S Loibl; M Untch; T Kühn
Journal:  Clin Exp Metastasis       Date:  2018-10-15       Impact factor: 5.150

2.  Lymphedema Symptom Intensity and Distress Surveys-Truncal and Head and Neck, Version 2.0.

Authors:  Sheila H Ridner; Jie Deng; Jennifer K Doersam; Mary S Dietrich
Journal:  Lymphat Res Biol       Date:  2020-11-12       Impact factor: 2.349

3.  Changes in volume and incidence of lymphedema during and after treatment with docetaxel, doxorubicin, and cyclophosphamide (TAC) in patients with breast cancer.

Authors:  Janine T Hidding; Carien H G Beurskens; Philip J van der Wees; Wilmy C A M Bos; Maria W G Nijhuis-van der Sanden; Hanneke W M van Laarhoven
Journal:  Support Care Cancer       Date:  2017-11-10       Impact factor: 3.603

4.  Content Validation of a Practice-Based Work Capacity Assessment Instrument Using ICF Core Sets.

Authors:  Johan H Sengers; Femke I Abma; Loes Wilming; Pepijn D D M Roelofs; Yvonne F Heerkens; Sandra Brouwer
Journal:  J Occup Rehabil       Date:  2021-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.